News
ACTU
0.3288
+0.55%
0.0018
Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data
NASDAQ · 4d ago
Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Benzinga · 4d ago
Actuate Therapeutics receives notice of allowance for Elraglusib patent
TipRanks · 6d ago
Weekly Report: what happened at ACTU last week (1026-1030)?
Weekly Report · 6d ago
Actuate Therapeutics Completes Public Equity and Warrant Offering
TipRanks · 10/28 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/27 17:05
Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings
Benzinga · 10/27 13:52
Actuate Therapeutics announces pricing of $11M public offering
TipRanks · 10/27 12:26
Actuate Therapeutics prices $11M public offering of stock and warrants
Seeking Alpha · 10/27 12:18
Actuate Therapeutics Prices ~$11M Offering Of 30,986M Common Shares, Warrants At $0.71 Per Unit
Benzinga · 10/27 12:07
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/27 12:05
Weekly Report: what happened at ACTU last week (1019-1023)?
Weekly Report · 10/26 09:22
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/19 12:05
Weekly Report: what happened at ACTU last week (1012-1016)?
Weekly Report · 10/19 09:22
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/19 08:46
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/16 21:05
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/16 17:05
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 10/16 08:46
Weekly Report: what happened at ACTU last week (1005-1009)?
Weekly Report · 10/12 09:24
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/07 17:05
More
Webull provides a variety of real-time ACTU stock news. You can receive the latest news about Actuate Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.